OSTEOPOROSIS AND HORMONE REPLACEMENT THERAPY
Abstract
BACKGROUND Osteoporosis affects almost every other woman after menopause. Fractures due to osteoporosis are a significant cause of disability and death, therefore we try to prevent themwith antiosteoporotic medications.Hormone replacement therapy (HRT) had been a mainstay of osteoporosis preventionand treatment for a long time, although only with the publication of the breakthroughWomen’s Health Initiative study in 2002 we got consistent data about beneficial effects ofHRT on bone mass and fracture prevention. Paradoxically, the same study provided alsodata on harmful cardiovascular effects of HRT and considerably limited its use in the field.However, more recent data showed that HRT is safe for younger women immediately aftermenopause, so it could be easily prescribed for vasomotor symptoms relief. At the sametime, HRT is beneficial for bones, as well. On the other hand, HRT is mainly not suitable forolder women and long-term treatment. CONCLUSIONS As older women are those who sustain the majority of osteoporotic fractures, HRT isleaving its main role in osteoporosis prevention and treatment to other drugs, first of all tobisphosphonates and strontium ranelateDownloads
The Author transfers to the Publisher (Zdravniški vestnik/Slovenian Medical Journal) all economic copyrights following form Article 22 of the Slovene Copyright and Related Rights Act (ZASP), including the right of reproduction, the right of distribution, the rental right, the right of public performance, the right of public transmission, the right of public communication by means of phonograms and videograms, the right of public presentation, the right of broadcasting, the right of rebroadcasting, the right of secondary broadcasting, the right of communication to the public, the right of transformation, the right of audiovisual adaptation and all other rights of the author according to ZASP.
The aforementioned rights are transferred non-exclusively, for an unlimited number of editions, for the term of the statutory
The Author can make use of his work himself or transfer subjective rights to others only after 3 months from date of first publishing in the journal Zdravniški vestnik/Slovenian Medical Journal.
The Publisher (Zdravniški vestnik/Slovenian Medical Journal) has the right to transfer the rights, acquired parties without explicit consent of the Author.
The Author consents that the Article be published under the Creative Commons BY-NC 4.0 (attribution-non-commercial) or comparable licence.
